New drug targets bile duct cancer in small trial
NCT ID NCT06178588
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers are checking if the tumors shrink and how safe the treatment is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab govitecan
- What this could lead to
- If it works, this could point toward a new treatment option for advanced bile duct cancer that has not responded to prior therapy.
- What could go wrong
- This is a very small, early-phase trial with only 15 participants, so results may not apply broadly. The drug can cause side effects like nausea, fatigue, and low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- Can a targeted pill outperform chemo for bile duct cancer?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- New chemo combo targets Hard-to-Treat liver cancer
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- New chemo mist targets abdominal cancer with fewer side effects